CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives $9.00 Average Price Target from Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been given an average rating of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $8.60.

CAMP has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a report on Friday, March 6th. Leerink Partners lifted their price target on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, April 2nd. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research report on Tuesday. They set a “buy” rating and a $7.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of CAMP4 Therapeutics in a research note on Monday, December 29th.

CAMP4 Therapeutics Stock Performance

NASDAQ:CAMP opened at $4.52 on Wednesday. The stock has a market capitalization of $234.67 million, a PE ratio of -1.70 and a beta of 0.41. CAMP4 Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $7.75. The company has a fifty day moving average of $4.59 and a two-hundred day moving average of $4.50.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, March 5th. The Wireless communications provider reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.56). The company had revenue of $0.35 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,298.54% and a negative return on equity of 162.49%. Research analysts forecast that CAMP4 Therapeutics will post -4.99 earnings per share for the current year.

Institutional Investors Weigh In On CAMP4 Therapeutics

Hedge funds have recently modified their holdings of the business. Bridgeway Capital Management LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth about $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in CAMP4 Therapeutics in the 4th quarter valued at about $61,000. Jefferies Financial Group Inc. purchased a new position in CAMP4 Therapeutics in the 4th quarter worth approximately $70,000. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics in the 4th quarter worth approximately $86,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.